{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T08:51:05Z","timestamp":1781945465329,"version":"3.54.5"},"reference-count":77,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T00:00:00Z","timestamp":1767830400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R21AG068608"],"award-info":[{"award-number":["R21AG068608"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry Letters"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.bmcl.2026.130536","type":"journal-article","created":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T16:50:37Z","timestamp":1767804637000},"page":"130536","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Discovery of multitargeting single agents as a novel route to the potential treatment of neurodegenerative diseases"],"prefix":"10.1016","volume":"133","author":[{"given":"Jeetal","family":"Vyas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anuj S.","family":"Jamenis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krishna","family":"Kaku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yesha","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin M.","family":"Miner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tarun N.","family":"Bhatia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roxanne E.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruoli","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernest","family":"Hamel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rehana K.","family":"Leak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleem","family":"Gangjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmcl.2026.130536_bb0005","doi-asserted-by":"crossref","first-page":"754","DOI":"10.2174\/1389557519666191104110908","article-title":"Parkinson\u2019s disease: A review from pathophysiology to treatment","volume":"20","author":"Marino","year":"2020","journal-title":"Mini Rev Med Chem"},{"key":"10.1016\/j.bmcl.2026.130536_bb0010","doi-asserted-by":"crossref","first-page":"49","DOI":"10.59556\/japi.72.0755","article-title":"Current update on promising new anti-Alzheimer\u2019s drugs in different phases of clinical development: where exactly are we lacking?","volume":"72","author":"Sharma","year":"2024","journal-title":"J Assoc Physicians India"},{"key":"10.1016\/j.bmcl.2026.130536_bb0015","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1002\/alz.12362","article-title":"Population estimate of people with clinical Alzheimer's disease and mild cognitive impairment in the United States (2020-2060)","volume":"17","author":"Rajan","year":"2021","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.bmcl.2026.130536_bb0020","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/s41531-022-00410-y","article-title":"Incidence of Parkinson disease in North America","volume":"8","author":"Willis","year":"2022","journal-title":"NPJ Parkinsons Dis"},{"key":"10.1016\/j.bmcl.2026.130536_bb0025","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1038\/d41586-025-01102-2","article-title":"Dementia treatment strives for new heights: drugs that clear brain plaques are a welcome arrival, but targeting amyloid-\u03b2 alone might not be enough to halt Alzheimer\u2019s disease","volume":"640","author":"Makin","year":"2025","journal-title":"Nature"},{"key":"10.1016\/j.bmcl.2026.130536_bb0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.pneurobio.2022.102270","article-title":"Amyloid beta, tau, and alpha-synuclein aggregates in the pathogenesis, prognosis, and therapeutics for neurodegenerative diseases","volume":"214","author":"Sengupta","year":"2022","journal-title":"Prog Neurobiol"},{"key":"10.1016\/j.bmcl.2026.130536_bb0035","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21145030","article-title":"Tau and alpha synuclein synergistic effect in neurodegenerative diseases: when the periphery is the core","volume":"21","author":"Vacchi","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.bmcl.2026.130536_bb0040","doi-asserted-by":"crossref","DOI":"10.1083\/jcb.202409104","article-title":"Synaptic sabotage: how tau and alpha-synuclein undermine synaptic health","volume":"224","author":"Uytterhoeven","year":"2025","journal-title":"J Cell Biol"},{"key":"10.1016\/j.bmcl.2026.130536_bb0045","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232112841","article-title":"Phosphorylated tau in Alzheimer\u2019s disease and other tauopathies","volume":"23","author":"Rawat","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.bmcl.2026.130536_bb0050","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1186\/s13195-022-01150-0","article-title":"Alpha-synuclein: a pathological factor with Abeta and tau and biomarker in Alzheimer\u2019s disease","volume":"14","author":"Shim","year":"2022","journal-title":"Alzheimer\u2019s Res Ther"},{"key":"10.1016\/j.bmcl.2026.130536_bb0055","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1038\/s41392-025-02179-x","article-title":"Protein kinases in neurodegenerative diseases: current understandings and implications for drug discovery","volume":"10","author":"Wu","year":"2025","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.bmcl.2026.130536_bb0060","doi-asserted-by":"crossref","first-page":"589","DOI":"10.3233\/JPD-171191","article-title":"C-Abl and Parkinson\u2019s disease: mechanisms and therapeutic potential","volume":"7","author":"Brahmachari","year":"2017","journal-title":"J Parkinsons Dis"},{"key":"10.1016\/j.bmcl.2026.130536_bb0065","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abp9352","article-title":"The c-Abl inhibitor IkT-148009 suppresses neurodegeneration in mouse models of heritable and sporadic Parkinson's disease","volume":"15","author":"Karuppagounder","year":"2023","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.bmcl.2026.130536_bb0070","doi-asserted-by":"crossref","DOI":"10.3390\/cells12162041","article-title":"The role of c-Abl tyrosine kinase in brain and its pathologies","volume":"12","author":"Motaln","year":"2023","journal-title":"Cells"},{"key":"10.1016\/j.bmcl.2026.130536_bb0075","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.neurobiolaging.2020.09.006","article-title":"Cognitive enhancement, TAU phosphorylation reduction, and neuronal protection by the treatment of an LRRK2 inhibitor in a tauopathy mouse model","volume":"96","author":"Castro-Sanchez","year":"2020","journal-title":"Neurobiol Aging"},{"key":"10.1016\/j.bmcl.2026.130536_bb0080","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1111\/ejn.14182","article-title":"The unlikely partnership between LRRK2 and alpha-synuclein in Parkinson's disease","volume":"49","author":"Cresto","year":"2019","journal-title":"Eur J Neurosci"},{"key":"10.1016\/j.bmcl.2026.130536_bb0085","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aar5429","article-title":"LRRK2 activation in idiopathic Parkinson's disease","volume":"10","author":"Di Maio","year":"2018","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.bmcl.2026.130536_bb0090","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1042\/CS20220067","article-title":"The emerging role of LRRK2 in tauopathies","volume":"136","author":"Herbst","year":"2022","journal-title":"Clin Sci (Lond)"},{"key":"10.1016\/j.bmcl.2026.130536_bb0095","doi-asserted-by":"crossref","DOI":"10.3390\/cells9122565","article-title":"Pathological functions of LRRK2 in Parkinson\u2019s disease","volume":"9","author":"Jeong","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.bmcl.2026.130536_bb0100","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/s41531-024-00660-y","article-title":"G2019S selective LRRK2 kinase inhibitor abrogates mitochondrial DNA damage","volume":"10","author":"Pena","year":"2024","journal-title":"NPJ Parkinsons Dis"},{"key":"10.1016\/j.bmcl.2026.130536_bb0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2020.105049","article-title":"LRRK2 kinase inhibitors reduce alpha-synuclein in human neuronal cell lines with the G2019S mutation","volume":"144","author":"Zhao","year":"2020","journal-title":"Neurobiol Dis"},{"key":"10.1016\/j.bmcl.2026.130536_bb0110","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23169355","article-title":"The omnipresence of DYRK1A in human diseases","volume":"23","author":"Deboever","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.bmcl.2026.130536_bb0115","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22116047","article-title":"Dual-specificity, tyrosine phosphorylation-regulated kinases (DYRKs) and cdc2-like kinases (CLKs) in human disease, an overview","volume":"22","author":"Lindberg","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.bmcl.2026.130536_bb0120","article-title":"Disruption of DYRK1A-induced hyperphosphorylation of amyloid-beta and tau protein in Alzheimer's disease: An integrative molecular modeling approach","volume":"9","author":"Shukla","year":"2022","journal-title":"Front Mol Biosci"},{"key":"10.1016\/j.bmcl.2026.130536_bb0125","doi-asserted-by":"crossref","first-page":"15847","DOI":"10.1038\/s41598-022-19967-y","article-title":"DYRK1A antagonists rescue degeneration and behavioural deficits of in vivo models based on amyloid-beta, tau and DYRK1A neurotoxicity","volume":"12","author":"Zhu","year":"2022","journal-title":"Sci Rep"},{"key":"10.1016\/j.bmcl.2026.130536_bb0130","doi-asserted-by":"crossref","first-page":"2820","DOI":"10.1096\/fj.08-120410","article-title":"Alpha-synuclein contributes to GSK-3beta-catalyzed tau phosphorylation in Parkinson\u2019s disease models","volume":"23","author":"Duka","year":"2009","journal-title":"FASEB J"},{"key":"10.1016\/j.bmcl.2026.130536_bb0135","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1007\/s11515-012-1222-2","article-title":"The role of GSK3beta in the development of the central nervous system","volume":"7","author":"Luo","year":"2012","journal-title":"Front Biol (Beijing)"},{"key":"10.1016\/j.bmcl.2026.130536_bb0140","doi-asserted-by":"crossref","first-page":"688","DOI":"10.34172\/apb.2023.071","article-title":"Role of GSK-3beta inhibitors: new promises and opportunities for Alzheimer\u2019s disease","volume":"13","author":"Shri","year":"2023","journal-title":"Adv Pharm Bull"},{"key":"10.1016\/j.bmcl.2026.130536_bb0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2022.103970","article-title":"Human tau accumulation promotes glycogen synthase kinase-3beta acetylation and thus upregulates the kinase: A vicious cycle in Alzheimer neurodegeneration","volume":"78","author":"Zhou","year":"2022","journal-title":"EBioMedicine"},{"key":"10.1016\/j.bmcl.2026.130536_bb0150","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.2147\/NDT.S166322","article-title":"The direct and indirect effects of alpha-synuclein on microtubule stability in the pathogenesis of Parkinson's disease","volume":"14","author":"Carnwath","year":"2018","journal-title":"Neuropsychiatr Dis Treat"},{"key":"10.1016\/j.bmcl.2026.130536_bb0155","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1093\/hmg\/ddab294","article-title":"Fine-mapping of Parkinson's disease susceptibility loci identifies putative causal variants","volume":"31","author":"Schilder","year":"2022","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.bmcl.2026.130536_bb0160","doi-asserted-by":"crossref","first-page":"343","DOI":"10.3389\/fncel.2015.00343","article-title":"Neurodegeneration and microtubule dynamics: death by a thousand cuts","volume":"9","author":"Dubey","year":"2015","journal-title":"Front Cell Neurosci"},{"key":"10.1016\/j.bmcl.2026.130536_bb0165","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1016\/j.drudis.2020.11.033","article-title":"Microtubule-targeting agents and neurodegeneration","volume":"26","author":"Boiarska","year":"2021","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.bmcl.2026.130536_bb0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejcb.2020.151075","article-title":"Microtubule-targeting agents and their impact on cancer treatment","volume":"99","author":"Cermak","year":"2020","journal-title":"Eur J Cell Biol"},{"key":"10.1016\/j.bmcl.2026.130536_bb0175","doi-asserted-by":"crossref","first-page":"8979","DOI":"10.1021\/jm301079z","article-title":"Microtubule stabilizing agents as potential treatment for Alzheimer\u2019s disease and related neurodegenerative tauopathies","volume":"55","author":"Ballatore","year":"2012","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2026.130536_bb0180","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/nrclinonc.2016.96","article-title":"Combine and conquer: challenges for targeted therapy combinations in early phase trials","volume":"14","author":"Lopez","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.bmcl.2026.130536_bb0185","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.3390\/ph18111685","article-title":"Multitarget-directed ligands for Alzheimer\u2019s disease: recent novel MTDLs and mechanistic insights","volume":"18","author":"Almaghrabi","year":"2025","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.bmcl.2026.130536_bb0190","doi-asserted-by":"crossref","first-page":"831","DOI":"10.3390\/ph18060831","article-title":"Multitarget compounds designed for Alzheimer, Parkinson, and Huntington neurodegeneration diseases","volume":"18","author":"Katsoulaki","year":"2025","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.bmcl.2026.130536_bb0195","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.3390\/molecules21121661","article-title":"Janus compounds, 5-chloro-N(4)-methyl-N(4)-aryl-9H-pyrimido[4,5-b]indole-2,4-diamines, cause both microtubule depolymerizing and stabilizing effects","volume":"21","author":"Rohena","year":"2016","journal-title":"Molecules"},{"key":"10.1016\/j.bmcl.2026.130536_bb0200","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1021\/acs.jmedchem.0c02146","article-title":"Addressing a trapped high-energy water: design and synthesis of highly potent pyrimidoindole-based glycogen synthase kinase-3beta inhibitors","volume":"65","author":"Andreev","year":"2022","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2026.130536_bb0205","doi-asserted-by":"crossref","first-page":"6922","DOI":"10.1021\/acs.jmedchem.3c01696","article-title":"Psychoplastogenic DYRK1A inhibitors with therapeutic effects relevant to Alzheimer\u2019s disease","volume":"67","author":"Warren","year":"2024","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2026.130536_bb0210","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1177\/2040620714537865","article-title":"Practical management of patients with chronic myeloid leukemia who develop tyrosine kinase inhibitor-resistant BCR-ABL1 mutations","volume":"5","author":"Ai","year":"2014","journal-title":"Ther Adv Hematol"},{"key":"10.1016\/j.bmcl.2026.130536_bb0215","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1021\/jm5014055","article-title":"Discovery and preclinical profiling of 3-[4-(morpholin-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]benzonitrile (PF-06447475), a highly potent, selective, brain penetrant, and in vivo active LRRK2 kinase inhibitor","volume":"58","author":"Henderson","year":"2015","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2026.130536_bb0220","series-title":"Schr\u00f6dinger Release 2025-1: Maestro","year":"2025"},{"key":"10.1016\/j.bmcl.2026.130536_bb0225","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1016\/j.jmb.2014.02.005","article-title":"The novel microtubule-destabilizing drug BAL27862 binds to the colchicine site of tubulin with distinct effects on microtubule organization","volume":"426","author":"Prota","year":"2014","journal-title":"J Mol Biol"},{"key":"10.1016\/j.bmcl.2026.130536_bb0230","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.chembiol.2017.05.016","article-title":"Triazolopyrimidines are microtubule-stabilizing agents that bind the vinca inhibitor site of tubulin","volume":"24","author":"Saez-Calvo","year":"2017","journal-title":"Cell Chem Biol"},{"key":"10.1016\/j.bmcl.2026.130536_bb0235","doi-asserted-by":"crossref","first-page":"2876","DOI":"10.1021\/acschembio.6b00529","article-title":"Chemically linked vemurafenib inhibitors promote an inactive BRAF(V600E) conformation","volume":"11","author":"Grasso","year":"2016","journal-title":"ACS Chem Biol"},{"key":"10.1016\/j.bmcl.2026.130536_bb0240","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.114054","article-title":"ARN25068, a versatile starting point towards triple GSK-3beta\/FYN\/DYRK1A inhibitors to tackle tau-related neurological disorders","volume":"229","author":"Demuro","year":"2022","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmcl.2026.130536_bb0245","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/s41421-023-00639-8","article-title":"Pharmacology of LRRK2 with type I and II kinase inhibitors revealed by cryo-EM","volume":"10","author":"Zhu","year":"2024","journal-title":"Cell Discov"},{"key":"10.1016\/j.bmcl.2026.130536_bb0250","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ccr.2005.01.007","article-title":"Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl","volume":"7","author":"Weisberg","year":"2005","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bmcl.2026.130536_bb0255","unstructured":"Thermofisher. Thermofisher Kinase Profiling Services."},{"key":"10.1016\/j.bmcl.2026.130536_bb0260","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1016\/0006-2952(90)90613-P","article-title":"Dolastatin 10, a powerful cytostatic peptide derived from a marine animal. Inhibition of tubulin polymerization mediated through the vinca alkaloid binding domain","volume":"39","author":"Bai","year":"1990","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.bmcl.2026.130536_bb0265","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.341","article-title":"LRRK2 inhibition potentiates PARP inhibitor cytotoxicity through inhibiting homologous recombination-mediated DNA double strand break repair","volume":"11","author":"Chen","year":"2021","journal-title":"Clin Transl Med"},{"key":"10.1016\/j.bmcl.2026.130536_bb0270","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1038\/sj.bjc.6603170","article-title":"AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL","volume":"94","author":"Weisberg","year":"2006","journal-title":"Br J Cancer"},{"key":"10.1016\/j.bmcl.2026.130536_bb0275","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1080\/15384047.2019.1595283","article-title":"Glycogen synthase kinase-3 beta inhibitors as novel cancer treatments and modulators of antitumor immune responses","volume":"20","author":"Sahin","year":"2019","journal-title":"Cancer Biol Ther"},{"key":"10.1016\/j.bmcl.2026.130536_bb0280","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/s41698-024-00614-w","article-title":"Targeting the DYRK1A kinase prevents cancer progression and metastasis and promotes cancer cells response to G1\/S targeting chemotherapy drugs","volume":"8","author":"Laham","year":"2024","journal-title":"NPJ Precis Oncol"},{"key":"10.1016\/j.bmcl.2026.130536_bb0285","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2023.106196","article-title":"A 14-day pulse of PLX5622 modifies alpha-synucleinopathy in preformed fibril-infused aged mice of both sexes","volume":"184","author":"Bhatia","year":"2023","journal-title":"Neurobiol Dis"},{"key":"10.1016\/j.bmcl.2026.130536_bb0290","doi-asserted-by":"crossref","DOI":"10.1016\/j.pneurobio.2022.102307","article-title":"alpha-Synucleinopathy exerts sex-dimorphic effects on the multipurpose DNA repair\/redox protein APE1 in mice and humans","volume":"216","author":"Miner","year":"2022","journal-title":"Prog Neurobiol"},{"key":"10.1016\/j.bmcl.2026.130536_bb0295","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1007\/s13311-021-01114-6","article-title":"Heat shock protein 70 as a sex-skewed regulator of alpha-Synucleinopathy","volume":"18","author":"Bhatia","year":"2021","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.bmcl.2026.130536_bb0300","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1002\/cne.24468","article-title":"Sensitivity and specificity of Phospho-Ser129 alpha-synuclein monoclonal antibodies","volume":"526","author":"Delic","year":"2018","journal-title":"J Comp Neurol"},{"key":"10.1016\/j.bmcl.2026.130536_bb0305","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1038\/s41531-022-00388-7","article-title":"Revisiting the specificity and ability of phospho-S129 antibodies to capture alpha-synuclein biochemical and pathological diversity","volume":"8","author":"Lashuel","year":"2022","journal-title":"NPJ Parkinsons Dis"},{"key":"10.1016\/j.bmcl.2026.130536_bb0310","doi-asserted-by":"crossref","first-page":"4006","DOI":"10.1016\/j.neuron.2023.11.020","article-title":"Serine-129 phosphorylation of \u03b1-synuclein is a trigger for physiologic protein-protein interactions and synaptic function","volume":"111","author":"Parra-Rivas","year":"2023","journal-title":"Neuron"},{"key":"10.1016\/j.bmcl.2026.130536_bb0315","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/s41531-023-00444-w","article-title":"Dynamic physiological alpha-synuclein S129 phosphorylation is driven by neuronal activity","volume":"9","author":"Ramalingam","year":"2023","journal-title":"NPJ Parkinsons Dis"},{"key":"10.1016\/j.bmcl.2026.130536_bb0320","doi-asserted-by":"crossref","first-page":"303","DOI":"10.3233\/JPD-171248","article-title":"Best practices for generating and using alpha-synuclein pre-formed fibrils to model Parkinson\u2019s disease in rodents","volume":"8","author":"Polinski","year":"2018","journal-title":"J Parkinsons Dis"},{"key":"10.1016\/j.bmcl.2026.130536_bb0325","doi-asserted-by":"crossref","first-page":"49071","DOI":"10.1074\/jbc.M208046200","article-title":"Phosphorylated alpha-synuclein is ubiquitinated in alpha-synucleinopathy lesions","volume":"277","author":"Hasegawa","year":"2002","journal-title":"J Biol Chem"},{"key":"10.1016\/j.bmcl.2026.130536_bb0330","doi-asserted-by":"crossref","first-page":"29739","DOI":"10.1074\/jbc.M600933200","article-title":"Phosphorylation of Ser-129 is the dominant pathological modification of alpha-synuclein in familial and sporadic Lewy body disease","volume":"281","author":"Anderson","year":"2006","journal-title":"J Biol Chem"},{"key":"10.1016\/j.bmcl.2026.130536_bb0335","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/s41531-023-00491-3","article-title":"Distribution of phosphorylated alpha-synuclein in non-diseased brain implicates olfactory bulb mitral cells in synucleinopathy pathogenesis","volume":"9","author":"Killinger","year":"2023","journal-title":"NPJ Parkinsons Dis"},{"key":"10.1016\/j.bmcl.2026.130536_bb0340","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1111\/bcp.13126","article-title":"Microtubule destabilising agents: far more than just antimitotic anticancer drugs","volume":"83","author":"Bates","year":"2017","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.bmcl.2026.130536_bb0345","series-title":"Stability properties of neuronal microtubules Cytoskeleton","first-page":"442","volume":"73","author":"Baas","year":"2016"},{"key":"10.1016\/j.bmcl.2026.130536_bb0350","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/s41580-022-00473-y","article-title":"Mechanisms of microtubule organization in differentiated animal cells","volume":"23","author":"Akhmanova","year":"2022","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.bmcl.2026.130536_bb0355","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/0092-8674(84)90273-3","article-title":"Distinct populations of microtubules: tyrosinated and nontyrosinated alpha tubulin are distributed differently in vivo","volume":"38","author":"Gundersen","year":"1984","journal-title":"Cell"},{"key":"10.1016\/j.bmcl.2026.130536_bb0360","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1038\/nrm3227","article-title":"Post-translational regulation of the microtubule cytoskeleton: mechanisms and functions","volume":"12","author":"Janke","year":"2011","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.bmcl.2026.130536_bb0365","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1126\/science.aai8764","article-title":"Microtubules acquire resistance from mechanical breakage through intralumenal acetylation","volume":"356","author":"Xu","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.bmcl.2026.130536_bb0370","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1038\/ncb3481","article-title":"Tubulin acetylation protects long-lived microtubules against mechanical ageing","volume":"19","author":"Portran","year":"2017","journal-title":"Nat Cell Biol"},{"key":"10.1016\/j.bmcl.2026.130536_bb0375","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s40035-023-00354-0","article-title":"Microtubule acetylation dyshomeostasis in Parkinson's disease","volume":"12","author":"Naren","year":"2023","journal-title":"Transl Neurodegener"},{"key":"10.1016\/j.bmcl.2026.130536_bb0380","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/nrclinonc.2009.186","article-title":"Taxanes: optimizing adjuvant chemotherapy for early-stage breast cancer","volume":"7","author":"Bedard","year":"2010","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.bmcl.2026.130536_bb0385","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1634\/theoncologist.12-3-271","article-title":"Targeting the microtubules in breast cancer beyond taxanes: the epothilones","volume":"12","author":"Cortes","year":"2007","journal-title":"Oncologist"}],"container-title":["Bioorganic & Medicinal Chemistry Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X2600003X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X2600003X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T08:22:10Z","timestamp":1781943730000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960894X2600003X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":77,"alternative-id":["S0960894X2600003X"],"URL":"https:\/\/doi.org\/10.1016\/j.bmcl.2026.130536","relation":{},"ISSN":["0960-894X"],"issn-type":[{"value":"0960-894X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discovery of multitargeting single agents as a novel route to the potential treatment of neurodegenerative diseases","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmcl.2026.130536","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"130536"}}